Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.4% year on year to $458.4 million. Its non-GAAP profit of $0.33 per share was 36.7% above analysts’ consensus estimates.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
A number of stocks fell in the pre-market session after President Trump announced "reciprocal tariffs" on all US imports, set at a minimum rate of 10%.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including Pediatrix Medical Group (NYSE:MD) and its peers.
Pediatrix Medical Group has been on fire lately. In the past six months alone, the company’s stock price has rocketed 51.5%, reaching $16 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 1.2% year on year to $502.4 million. Its non-GAAP profit of $0.51 per share was 39.9% above analysts’ consensus estimates.
Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company projects 2025 adjusted EBITDA of $215 million–$235 million.
